{"id":914143,"date":"2025-11-26T16:11:30","date_gmt":"2025-11-26T21:11:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/"},"modified":"2025-11-26T16:11:30","modified_gmt":"2025-11-26T21:11:30","slug":"celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium"},"content":{"rendered":"
\n

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data.<\/p>\n

Abstract presentation details are provided below.<\/p>\n

\n Abstract Title:\u00a0<\/strong>Gedatolisib, a multi-target PI3K\/AKT\/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+\/HER2-\/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial
Author:<\/strong> Barbara Pistilli, MD
Presentation number:\u00a0<\/strong>RF7-04
Session Title: <\/strong>Rapid Fire 7
Presentation Date: <\/strong>December 11, 2025<\/p>\n

For more details about SABCS please visit:\u00a0https:\/\/www.sabcs.org\/<\/u><\/a>.<\/p>\n

\n About Celcuity<\/strong>\n <\/p>\n

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company’s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1\/2 inhibitor that comprehensively blockades the PI3K\/AKT\/mTOR (\u201cPAM\u201d) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K\u03b1, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+\/HER2- ABC has completed enrollment and the company has reported detailed results for the PIK3CA<\/em> wild-type cohort, and has completed enrollment of patients for the PIK3CA <\/em>mutant cohort. \u00a0A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4\/6 inhibitor and fulvestrant as first-line treatment for patients with HR+\/HER2- ABC is currently enrolling patients. A Phase 1\/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity\u2019s active clinical trials can be found at\u00a0ClinicalTrials.gov<\/u><\/a>. Celcuity is headquartered in Minneapolis.\u00a0Further information about Celcuity can be found at\u00a0www.celcuity.com<\/u><\/a>. Follow us on\u00a0LinkedIn<\/a> and\u00a0X<\/u><\/a>.<\/p>\n

\n View source version of release on GlobeNewswire.com<\/a>\n <\/p>\n

\n Contacts:<\/strong>\u00a0<\/p>\n

Celcuity Inc.\u00a0
Brian Sullivan, bsullivan@celcuity.com<\/a>\u00a0
Vicky Hahne, vhahne@celcuity.com<\/a>\u00a0
(763) 392-0123\u00a0<\/p>\n

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com<\/a>\u00a0
(415) 513-1284<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data. Abstract presentation details are provided below. Abstract Title:\u00a0Gedatolisib, a multi-target PI3K\/AKT\/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+\/HER2-\/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trialAuthor: Barbara Pistilli, MDPresentation number:\u00a0RF7-04Session … <\/p>\n

Continue reading “Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-914143","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCelcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data. Abstract presentation details are provided below. Abstract Title:\u00a0Gedatolisib, a multi-target PI3K\/AKT\/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+\/HER2-\/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trialAuthor: Barbara Pistilli, MDPresentation number:\u00a0RF7-04Session … Continue reading "Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T21:11:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2025-11-26T21:11:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":402,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=\",\"datePublished\":\"2025-11-26T21:11:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data. Abstract presentation details are provided below. Abstract Title:\u00a0Gedatolisib, a multi-target PI3K\/AKT\/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+\/HER2-\/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trialAuthor: Barbara Pistilli, MDPresentation number:\u00a0RF7-04Session … Continue reading \"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-26T21:11:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium","datePublished":"2025-11-26T21:11:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/"},"wordCount":402,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/","name":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=","datePublished":"2025-11-26T21:11:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MjkyNCM3Mjk0NDY2IzIxNTcwMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=914143"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914143\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=914143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=914143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=914143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}